Prognostication in Advanced Cancer: A Study Examining an Inflammation-Based Score Michael Partridge, MBChB, Marie Fallon, MBChB, MRCGP, FRCP, MD, Caroline Bray, MSc, Donald McMillan, PhD, Duncan Brown, MBChB, MD, FRCP, Barry Laird, MBChB, MRCGP, MD, DRCOG, DFFP Journal of Pain and Symptom Management Volume 44, Issue 2, Pages 161-167 (August 2012) DOI: 10.1016/j.jpainsymman.2011.08.013 Copyright © 2012 U.S. Cancer Pain Relief Committee Terms and Conditions
Fig. 1 The relationship between mGPS and survival. The maximum survival times for mGPS 0, 1, and 2 were 57.1, 30.9, and 36.0 weeks, respectively. mGPS=modified Glasgow Prognostic Score. Journal of Pain and Symptom Management 2012 44, 161-167DOI: (10.1016/j.jpainsymman.2011.08.013) Copyright © 2012 U.S. Cancer Pain Relief Committee Terms and Conditions